![]() |
|
|
Forward to a colleague |
||
Access Full Stories Scientists have made use of a new method for analysing gene expression to interrogate the whole genome for the causes of familial combined hyperlipidemia - an inherited disease that can contribute to high cholesterol... Read Invitrogen and Agilent settle differences After several years, Invitrogen and Agilent have at last settled patent infringement court cases concerning tools used in complementary DNA synthesis, polymerase chain reaction (PCR) and other molecular biology... Read Beckman Coulter sees earnings drop in Q4 Beckman Coulter saw its fourth quarter earnings held back by acquisition costs that overshadowed a near 11 per cent hike in revenues... Read Synthetic biology firm Geneart in the ascendency Germany's Geneart, a specialist in synthetic biology, is expecting strong growth in 2008 on the back of strong demand for gene synthesis. ... Read DNA extraction for all, says Mole Genetics Mole Genetics has launched its low cost, benchtop personal DNA extraction/purification system to the European market, making DNA research more accessible to smaller laboratories... Read |
|||||||||||||||||
All News Headlines for: February | January | December |
|||||||||||||||||
|
Related Industry News Missing link to the citric acid cycle found Researchers claim to have found the missing piece in the puzzle of how to artificially recreate the citric acid cycle - an essential part of aerobic respiration. The discovery could lead to plentiful supplies of... Read Tufts heralds outsourcing as the way of the future The trend towards outsourcing and outside partnering to improve drug development is tipped to continue, with the strategy being heralded as the way of the future in new research produced by the Tufts Center for... Read CML bigs up its US API biz Cambridge Major Laboratories (CML) said it is planning to execute a $30m expansion project which will spawn one of most modern active pharmaceutical ingredient (API) manufacturing sites in North America... Read Synthesis stumbling blocks in pharma licensing With increasing pressures on pharma pipelines leading to greater interest in compound licensing, firms can be caught out by failing to give scalability issues due attention, according to Joseph D'Antuono speaking... Read
|
|||||||||||||||||
|
|||||
Forward to a colleague |
|||||
To continue to receive this newsletter in your inbox, please add newsletter@LabTechnologist.com to your address book |
||
Update preferences | Change your email address | Unsubscribe |
||
Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback |
||
| © 2008 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com |
||